Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LINKER-MM3: linvoseltamab versus EPd in relapsed/refractory multiple myeloma
MOH_2023-10-30_013021Phase 3Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of linvoseltamab in multiple myeloma (MM) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Progression-free survival. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
linvoseltamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2023-10-30_013021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-10-30_013021.